It is well-known that increased TNF levels associate with disease exacerbations in SLE and in vitro data support that hydroxychloroquine decreases TNF-signalling by targeting the endosomal NADPH oxidase (34, 35). Here, FMO5 is linked to systemic lupus erythematosus.